Coegin Pharma AB ("Coegin" or the "Company") today announces that it has received its first limited purchase order for the Company's newly introduced high-performance cosmetic scalp serum within the Follicopeptide® portfolio. The order has been placed by Gents, an existing commercial partner of Coegin Pharma, ahead of the planned market launch.

The order represents an early commercial step in Coegin's strategy to expand the Follicopeptide portfolio with additional science-based products that broaden the offering and increase market reach.

As previously communicated, the scalp serum is designed to function both as a high-performance stand-alone cosmetic hair product and as an integrated part of the Follicopeptide portfolio. The formulation helps optimise the scalp environment while enhancing the overall user experience of Follicopeptide® Gel Serum.

Production is fully outsourced to an established cosmetic manufacturing partner in Denmark, enabling rapid and scalable market introduction while allowing Coegin to maintain full operational focus on scaling in-house production of Follicopeptide® Gel Serum. 

Jens Eriksson, CEO of Coegin Pharma, comments:
"Receiving the first purchase order already ahead of launch confirms strong partner interest as we expand the Follicopeptide portfolio. A broader product ecosystem strengthens our commercial offering and supports scalable growth with our partners."

Jenny Rydhström, CEO of GENTS, comments:
"We see strong potential in expanding our hairloss product range with Power Instant Hair Thickening Gel, which will be the commercial product name when it reaches our shelves at consumer level. It fits well within our premium grooming portfolio, and we look forward to introducing it to our customers."

The order represents a further step in Coegin Pharma's transition toward a commercially driven innovation company within hair and skin.

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology. Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com 

Attached files